- •Chapter 1
- •Ocular Adnexal Lymphoproliferative
- •1.1 Pathogenesis
- •1.2 Chronic Antigen Stimulation
- •1.3 Immunosuppression
- •1.4 Pathology
- •1.5 Cytogenetics
- •1.6 Clinical Features
- •1.7 Imaging Findings
- •1.8 Staging
- •1.9 Positron Emission Tomography
- •1.10 Treatment
- •1.11 Follicular Lymphoma
- •1.12 Mantle Cell Lymphoma
- •1.13 Radiotherapy
- •1.14 Chemotherapy
- •1.15 Immunotherapy
- •1.16 Radioimmunotherapy
- •1.17 Outcome
- •1.18 The Future
- •References
- •Chapter 2
- •2.1 General Introduction
- •2.2 The Aging Process and Facial Analysis
- •2.3 Endoscopic Brow Lift
- •2.3.1 Introduction
- •2.3.2 Endoscopic Browlift Anesthesia Pearls
- •2.3.4 Endoscopic Browlift Postoperative Care Pearls
- •2.4 Upper Blepharoplasty
- •2.4.1 Introduction
- •2.4.2 Patient Evaluation
- •2.4.3 Upper Blepharoplasty Anesthesia Pearls
- •2.4.4 Upper Blepharoplasty Surgical Procedure Pearls
- •2.5 Lower Blepharoplasty, Fillers, and Midface Augmentation
- •2.5.1 Introduction
- •2.5.2 Patient Evaluation
- •2.5.3 Lower Blepharoplasty Anesthesia Pearls
- •2.5.4 Lower Blepharoplasty Surgical Procedure Pearls
- •References
- •Chapter 3
- •3.1 Introduction
- •3.2 What Is the Diagnosis?
- •3.2.1 Pitfalls of Diagnosis
- •3.2.2 A Diagnostic Corticosteroid Trial?
- •3.2.3 The Question of Biopsy
- •3.3 Treatment
- •3.3.1 Corticosteroids
- •3.3.2 Radiation
- •3.3.3 Other Agents
- •3.4 Special Circumstances
- •3.4.1 Pediatric IOIS
- •3.4.2 Sclerosing Pseudotumor
- •3.4.3 Tolosa–Hunt Syndrome
- •References
- •Chapter 4
- •4.1 Introduction
- •4.2 Embryology, Anatomy, Physiology, and Pathophysiology of the Canalicular System
- •4.3 Infective Causes
- •4.3.1 Periocular Herpes Simplex Infection
- •4.3.2 Bacterial Canaliculitis
- •4.4.1 Lichen Planus
- •4.4.2 Ocular Cicatricial Pemphigoid
- •4.5 Iatrogenic Causes
- •4.5.1 Systemic Drugs
- •4.5.1.2 Docetaxel (Taxotere)
- •4.5.2 Radiotherapy
- •4.5.3 Topical Ophthalmic Treatments
- •4.5.3.2 Mitomycin C (MMC) Therapy
- •4.5.4 Lacrimal Stents and Plugs
- •4.6 The Surgical Approach to Managing Canalicular Disease
- •4.6.1 Surgical Technique for Dacryocystorhinostomy with Retrograde Canaliculostomy
- •References
- •Chapter 5
- •5.1 Introduction
- •5.2 Nomenclature
- •5.3 Clinical Manifestations of NF1
- •5.4 Orbitofacial Tumors in NF1
- •5.4.2 Malignant Peripheral Nerve Sheath Tumors
- •5.4.3 Optic Pathway Gliomas
- •5.5 Genetics
- •5.5.1 The NF1 Gene
- •5.5.2 Overlapping NF1-Like Phenotype (SPRED1)
- •5.6.1 Introduction
- •5.7 Surgical Management of Orbitofacial Tumors in NF1
- •5.7.1 Introduction
- •5.7.2 Timing of Surgery
- •5.7.3 Periorbital Involvement
- •5.7.3.1 The Upper Eyelid
- •5.7.3.2 The Lower Eyelid and Midface
- •5.7.4 Orbital Involvement
- •5.7.4.1 Proptosis
- •5.7.4.3 Proptosis Due to Optic Nerve Glioma
- •5.7.4.4 Orbital Enlargement with Dystopia and Hypoglobus
- •5.8 The Natural History of NF1 Tumor Growth from Birth to Senescence
- •References
- •Chapter 6
- •6.1 Introduction
- •6.2 Surgical Anatomy of the Lacrimal Drainage System
- •6.3 Basic Diagnostics for Disorders of the Lacrimal Drainage System
- •6.4 Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy
- •6.5.1 Case A
- •6.5.2 Case B
- •6.5.3 Case C
- •6.5.4 Case D
- •6.5.5 Case E
- •6.5.6 Case F
- •6.5.7 Case G
- •References
- •Chapter 7
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Patients
- •7.2.2 Examination
- •7.3 Results
- •7.3.1 Patient Data
- •7.3.3 Family History
- •7.3.4 Pregnancy History
- •7.3.5 Birth
- •7.3.6 Associated Systemic and Ocular Diseases
- •7.3.8 Neuroradiological Findings (Brain MRI)
- •7.3.9 Nasolacrimal System Findings
- •7.4 Discussion
- •7.4.1 Patients
- •7.4.2 Obstetric and Family History
- •7.4.3 Associated Pathologies
- •7.4.3.1 Ophthalmological Findings in Unilateral Disease
- •7.4.3.2 Neuroradiological Findings
- •7.4.3.3 Systemic Diseases
- •7.4.3.4 Nasolacrimal Duct Findings
- •7.5 Conclusions
- •References
- •Chapter 8
- •8.1 Introduction
- •8.2 Evaluation of Complicated Ptosis
- •8.2.1 Compensatory Eyebrow Elevation
- •8.2.3 Innervation Patterns of the Frontalis Muscle
- •8.2.4 Checklist of Preoperative Evaluation of Complicated Ptosis
- •8.3 Surgical Technique of Levator Muscle Recession
- •8.3.1 Principle
- •8.3.2 Approach to the Levator
- •8.3.3 Partial Levator Recession
- •8.3.4 Total Levator Recession
- •8.3.6 Undercorrection and Overcorrection
- •8.4 Surgical Technique of Brow Suspension
- •8.4.1 Materials for Brow Suspension
- •8.4.1.1 Nonautogenous Materials
- •8.4.1.2 Autogenous Fascia Lata
- •8.4.2 Our Technique of Harvesting Autogenous Fascia Lata
- •8.4.3 Mechanical Principals of Brow Suspension
- •8.4.4 Upper Lid Approach
- •8.4.5 Fascia Implantation
- •References
- •Chapter 9
- •Modern Concepts in Orbital Imaging
- •9.1 Computerized Tomography
- •9.2 Three-Dimensional Imaging
- •9.3 Magnetic Resonance Imaging
- •9.3.1 The T1 Constant
- •9.3.2 The T2 Constant
- •9.3.3 Creating the MR Image
- •9.4 Imaging of Common Orbital Lesions
- •9.4.1 Adenoid Cystic Carcinoma
- •9.4.2 Cavernous Hemangioma
- •9.4.3 Dermoid Cyst
- •9.4.4 Fibrous Dysplasia
- •9.4.5 Lymphangioma
- •9.4.6 Lymphoma
- •9.4.7 Myositis
- •9.4.8 Optic Nerve Glioma
- •9.4.9 Pseudotumor
- •9.4.10 Rhabdomyosarcoma
- •9.6 Positron Emission Tomography
- •9.7 Orbital Ultrasound
- •9.7.1 Physics and Instrumentation
- •9.7.1.1 Topographic Echography
- •9.7.1.2 Quantitative Echography
- •9.7.1.3 Kinetic Echography
- •9.7.2 Extraocular Muscles
- •9.7.3 Optic Nerves
- •References
- •Chapter 10
- •10.1 Introduction
- •10.3 Etiology
- •10.4 Microbiology
- •10.5 Changing Pathogens and Resistance
- •10.5.2 Orbital MRSA
- •10.6 Evaluation of Orbital Cellulitis
- •10.7 Medical Treatment of Orbital Cellulitis
- •10.8 Surgical Treatment of Orbital Cellulitis
- •10.9 Prevention of Orbital Cellulitis After Orbital Fracture
- •References
- •Chapter 11
- •11.1 Clinical Picture
- •11.1.1 Clinical Phases
- •11.2 Ocular Complications
- •11.3 Investigation
- •11.3.1 Angiography
- •11.4 Management
- •11.4.1 Active Nonintervention
- •11.4.2 Indications for Treatment
- •11.5 Modalities of Treatment
- •11.5.1 Steroids
- •11.5.1.1 Topical Steroids
- •11.5.1.2 Intralesional Corticosteroid Injection
- •11.5.1.3 Oral Corticosteroids
- •11.5.2 Interferon-Alfa
- •11.5.3 Vincristine
- •11.5.4 Laser
- •11.5.5 Embolization
- •11.5.6 Surgery
- •References
- •Chapter 12
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Biological Behavior and Timing of Metastasis
- •12.4 Lateralization
- •12.5 Localization
- •12.6 Clinical Features
- •12.7 Imaging and Patterns of Orbital Metastatic Disease
- •12.8 Biopsy
- •12.9 Common Types of Orbital Metastases
- •12.9.1 Breast Carcinoma
- •12.9.2 Lung Carcinoma
- •12.9.3 Prostatic Cancer
- •12.9.4 Melanoma
- •12.9.5 Carcinoid Tumor
- •12.11 Treatment
- •12.11.1 Radiotherapy
- •12.11.2 Chemotherapy
- •12.11.3 Hormonal Therapy
- •12.11.4 Surgery
- •12.12 Prognosis and Survival
- •References
- •Chapter 13
- •13.1 Introduction
- •13.2 Rituximab
- •13.3 Yttrium-90-Labeled Ibritumomab Tiuxetan
- •13.4 Imatinib Mesylate
- •13.5 Cetuximab
- •References
- •Chapter 14
- •14.1 Introduction
- •14.2 Porous Orbital Implants
- •14.3 Orbital Implant Selection in Adults
- •14.4 Orbital Implant Selection in Children
- •14.5 Volume Considerations in Orbital Implant Selection
- •14.7 Which Wrap to Use
- •14.8 To Peg or Not to Peg Porous Implants
- •14.9 Summary
- •References
- •Chapter 15
- •15.1 Introduction
- •15.2 Etiology and Presentation
- •15.2.1 Etiology of Orbital Volume Loss
- •15.2.2 Etiology of Periorbital Volume Loss
- •15.2.3 Features of Orbital Volume Loss
- •15.2.4 Features of Periorbital Volume Loss
- •15.3 Background to Injectable Soft-Tissue Fillers
- •15.3.1 Historical Perspective on Volume Replacement
- •15.4 Types of Injectable Soft-Tissue Filler
- •15.4.1 Collagen Fillers
- •15.4.2 Hyaluronic acid Fillers
- •15.5 Treatment Areas
- •15.5.1 Orbit
- •15.5.2 Upper Eyelid and Brow
- •15.5.3 Tear Trough
- •15.5.4 Temple and Brow
- •15.6 Other Periorbital Uses of Injectable Soft-Tissue Fillers
- •15.6.1 Upper Eyelid Loading
- •15.6.2 Lower Eyelid Elevation
- •15.6.3 Treatment of Cicatricial Ectropion
- •15.7 Future Developments
- •References
74 |
4 Lacrimal Canalicular Inflammation and Occlusion: Diagnosis and Management |
Summary for the Clinician
■ There are many causes for canalicular dysfunction, and symptoms can vary according to the
4severity and duration of the underlying disease.
■Local infective causes can include herpes simplex and bacterial canaliculitis.
■Systemic inflammatory causes include LP, ocular cicatricial pemphigoid, SJS.
■Topical medications can be a cause of canalicular obstruction.
■Radiation can have a secondary effect that causes an obstruction.
■Systemic medications such as Taxotere can also lead to canalicular scarring. Proper dosing can reduce the incidence of this.
■Topical ophthalmic treatments can cause canalicular scarring.
■Medications with preservatives can induce chronic inflammation.
■MMC therapy used for the treatment of ocular surface malignancy can produce canalicular disease in approximately 21% of patients.
■Lacrimal stents and plugs may sometimes incite a mucosal inflammatory response, which may lead to secondary fibrosis and the risk of canalicular stenosis.
4.6The Surgical Approach to Managing Canalicular Disease
A micropunctoplasty, such as the three-snip procedure, is useful if punctal stenosis is present with a patent canaliculus and nasolacrimal duct or extreme punctal stenosis prevents canalicular assessment. The purpose is to remove the posterior wall of both the punctal ampulla and 1–2 mm proximal canaliculus, although recent evidence suggests that removal of the posterior ampullary wall alone, without disruption of the canaliculus, may be preferable [7].
In performing a standard punctoplasty, a punctum seeker may be required first to identify and enter the lacrimal punctum, which may then be further dilated with the wider-tipped Nettleship dilator. Three incisions are then made with either a pair of fine Westcott or Vannas scissors; a vertical incision is made through the most posterolateral part of the punctum and ampulla, a second along the avascular superior margin of the canaliculus, and the third removes the flap of tissue thus created.
For complete punctal occlusion, the tip of a 19-gauge needle is inserted bevel up and obliquely—under microscopic illumination—into the punctal “hill” at an angle almost in line with the (presumed) canalicular lumen. The cutting edge of the needle is advanced medially while slowly rotating to bevel down to open the proximal canaliculus. Failure to identify the mucosal-lined lumen signifies a more extensive block, and the patient should be offered open lacrimal drainage surgery with retrograde intubation (discussed in the next section).
If there is complete closure of the canaliculi, external DCR with retrograde intubation should be offered. Although resistance to outflow may appear to be limited to a small segment of a canaliculus (or canaliculi), DCR is advocated for three reasons: First, the full extent of canalicular disease is impossible to determine by probing and may be limited to only a short proximal segment. Second, bypassing the physiological resistance of the nasolacrimal duct with DCR reduces the overall resistance to tear flow, and this will aid drainage, even if canalicular dynamics remain impaired. Third, it is known that some patients will require a secondary bypass tube—even if the reconstructed anastomosis is anatomically patent—and this is best achieved after prior open DCR and carunculectomy.
4.6.1Surgical Technique for Dacryocystorhinostomy with Retrograde Canaliculostomy
If canalicular occlusion occurs within the proximal 7 mm, DCR with retrograde canaliculostomy is the procedure of choice; this marsupializes the healthy distal canaliculus into the conjunctival sac. The extent of canalicular block is established only at surgery, and since a healthy common canaliculus is required to perform retrograde canaliculostomy, the patient should be warned of the possible need for a primary glass bypass tube in the event that no common canaliculus is found. In all cases, carunculectomy should be performed as later placement of a bypass tube is more successful within a previously healed carunculectomy bed.
A large osteotomy should be created as this allows versatility in the positioning of any subsequent Jones canalicular bypass tube. After suturing of the posterior mucosal flaps, the internal common canalicular opening is entered retrogradely using a “1”-gauge Bowman probe that has been bent perpendicularly at about 8–9mm from its end. The probe is passed as far laterally as possible along each canaliculus, and a 1- to 2-mm fenestration is created in the canalicular wall overlying the tip of the probe (Fig. 4.5a); the “pseudopuncta” are intubated, and the DCR is completed in a standard
|
4.6 |
The Surgical Approach to Managing Canalicular Disease |
75 |
a |
b |
c |
|
Fig. 4.5 (a) DCR with retrograde canaliculostomy: “1” probe (chevron) with a perpendicular bend at its end, is placed retrograde into the canaliculus, and canaliculostomy performed with an E11 blade over most lateral part of upper canaliculus to create pseudopunctum (long arrow), this being medial to normal punctum (short arrow). (b) Primary placement of Jones bypass tube: passage of a “bullhorn” dilator through the medial tissues and (c) passage of the glass tube into the tract over a “1” probe
fashion. If only the common canaliculus is present, its lateral end should be opened into the carunculectomy bed; in this case, and others where only a single canaliculus is retrievable, the returning end is passed through the heavily scarred annulus of the opposite punctum and forced medially through the lid tissues.2 This last manœuvre is assisted by passing a large-bore needle through the tissue first to create a track that enters the upper part of the opened sac, remote from the common canalicular opening.
The patient should be reviewed at about 1 week for removal of sutures and again at 3–4 weeks after surgery for removal of the silicone intubation; by this time, the pseudopunctum will typically have completely healed. “Cheese wiring” of the pseudopuncta will occur within a month if neither end of the stent is returning to the nose through a healthy collagen annulus, and such intubation should be removed at about 3 weeks after surgery.
4.6.2Placement of a Jones Canalicular Bypass Tube3
Primary or secondary placement of a Jones canalicular bypass tube is required if no functioning canalicular tissue is present, with the tube designed to act as a sump drain, permitting gravitational tear flow from the medial tear lake into the nose, aided by the slight subatmospheric pressure in the nose that occurs during inhalation.
Primary placement of a tube during DCR is undertaken after posterior mucosal suturing; the tube requires a 30° downward tilt for optimum drainage, with the distal
2 Monocanalicular stenting is unlikely to stay in place because of the absence of a normal annulus at the pseudopunctum.
3 T his is sometimes referred to as a canaliculo-dacrocystorhi- nostomy or CDCR.
end lying free within the nasal space, somewhat in front of the middle turbinate, and the proximal end positioned hard behind the lower lid margin and immediately posterior to the medial canthal tendon. The mouth of the tube should lie neither too deeply (where it may abut the epibulbar surface) nor too anteriorly (where it will lie proud of the tear lake). After primary placement, the tube should be held somewhat laterally—by passing a 6–0 nylon suture three times around the neck of the tube— with each end of the suture passed through the skin beneath the lower canaliculus and tied over a bolster (fig 4.1c); the tube end is thereby lifted clear of the caruncular bed while conjunctival healing occurs in this area.
Secondary placement of a Jones bypass tube is best accomplished by using a Nettleship dilator to pierce the epithelium at the exact desired position and a track forced through to the nose using the smallest end of the doubleended (“bullhorn”) dilators supplied with commercial tube sets (Fig. 4.5b). An appropriate tube (commonly 11 mm, with a 3.5-mm flange) is placed onto a “1”-gauge lacrimal probe that is passed along the dilated track, and the tube is forced along the track using the end of the thumbnails (Fig. 4.5c); the use of any form of instrument on the tube flange tends to shatter it. The positions of the ocular and nasal ends of the tube should be checked after withdrawing the “1” probe and spontaneous flow of saline verified. Since the patient will previously have had a carunculectomy, the bed of which will have healed, a suture need not be placed around the neck of the tube.
Nasal examination, preferably with endoscopy, although a headlight and speculum are often adequate, aids secondary placement of bypass tubes. Placement is best performed under a short general anesthetic as the vasoconstriction of nasal local anesthesia creates an atypically capacious nasal space and leads to the misguided nasal positioning of the bypass tube.
